XBIO Latest Press Releases

-- August 7, 2026 --

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform ACCESS Newswire 8:35 AM

-- June 4, 2026 --

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma ACCESS Newswire 8:40 AM

-- June 1, 2026 --

Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival ACCESS Newswire 9:02 AM

-- May 13, 2026 --

Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform ACCESS Newswire 8:05 AM

-- April 22, 2026 --

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting ACCESS Newswire 9:00 AM

-- March 13, 2026 --

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results ACCESS Newswire 8:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software